Randomized trial · people

Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this phase 2 trial, survodutide lowered bodyweight more than placebo at every dose tested, with larger losses at higher doses and gut side effects in most people taking it.

Kind
Randomized trial
Studied in
People
Number studied
387
Published
2024
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested how safe and well tolerated survodutide was for obesity management, and how much bodyweight it took off at different doses.

How the study was done

A randomized, double-blind, placebo-controlled phase 2 trial in 387 adults aged 18 to 75 with a BMI of 27 kg/m2 or more and no diabetes, at 43 centers in 12 countries. People got once-weekly shots of survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo (a dummy shot) for 46 weeks: 20 weeks of dose increases, then 26 weeks at the set dose.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average bodyweight change at week 46 was -6.2% in the 0.6 mg arm, -12.5% in the 2.4 mg arm, -13.2% in the 3.6 mg arm and -14.9% in the 4.8 mg arm, compared with -2.8% on placebo. Weight loss grew with the dose. Side effects showed up in 281 of 309 (91%) people on survodutide and 58 of 77 (75%) on placebo. Most were gut-related: 232 of 309 (75%) on survodutide and 32 of 77 (42%) on placebo.

What it doesn’t show

This was a 46-week dose-finding trial in adults without diabetes, and only 233 of 386 treated people (60.4%) finished the full treatment period. The trial was funded by Boehringer Ingelheim.

The paper

le Roux et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024.

The compound

More studies on Survodutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo